Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Documenti analoghi

• Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
  di: Lampelj, Maja, et al.
  Pubblicazione: (2015)
• Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.
  di: Sebastian Zukowski, et al.
  Pubblicazione: (2008-06-01)
• Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1
  di: Sipley, John D., et al.
  Pubblicazione: (1997)
• Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
  di: Bouchet, C., et al.
  Pubblicazione: (1998)
• The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
  di: Banys-Paluchowski, Malgorzata, et al.
  Pubblicazione: (2019)